ICU中利奈唑胺浓度极端变异:常规治疗药物监测的必要性
本文报告一例66岁ICU患者因耐万古霉素屎肠球菌腹膜炎和脓胸接受利奈唑胺治疗。标准剂量600 mg每12小时静脉给药下,利奈唑胺浓度持续低于定量下限达6天,且VRE持续分离。改为连续输注2400 mg/天后达到治疗水平(Cmean 6.17 mg/L),但随后出现超治疗暴露(Cmean 12.12 mg/L;24小时AUC 290.9 mg·h/L)并导致肾上腺素能毒性。利奈唑胺清除率从14.6降至6.2 L/h,与肾功能无关。案例强调ICU患者利奈唑胺药代动力学极端个体内变异,常规TDM对优化治疗至关重要。
要点
- ICU患者利奈唑胺标准剂量下浓度可能持续低于定量下限,导致治疗失败。
- 连续输注可在间歇给药失败时达到药效学目标,但需TDM避免超治疗暴露。
- 利奈唑胺清除率下降与肾功能无关,提示非线性消除和替代代谢途径影响。
核心结论
- 常规TDM对ICU患者利奈唑胺治疗的安全有效管理至关重要。
- 本案例强调将TDM与药代动力学建模结合以指导复杂动态临床场景中的个体化给药策略。
研究设计与样本
- 单例病例报告:66岁ICU患者,因VRE腹膜炎和脓胸接受利奈唑胺治疗。
主要发现
- 标准剂量600 mg IV每12小时下,利奈唑胺浓度持续低于定量下限达6天, coinciding with persistent VRE isolation。
- 改为连续输注2400 mg/天后达到治疗水平(Cmean 6.17 mg/L)。
- 随后出现超治疗暴露(Cmean 12.12 mg/L;24小时AUC 290.9 mg·h/L),导致肾上腺素能毒性。
- 利奈唑胺清除率从14.6降至6.2 L/h,与肾功能无关,提示非线性消除和替代代谢途径影响。
- 脓胸引流和氯胺酮停用后,PK参数稳定。
关键数值与推荐
- 治疗水平:Cmean 6.17 mg/L(连续输注2400 mg/天时)。
- 超治疗暴露:Cmean 12.12 mg/L;24小时AUC 290.9 mg·h/L。
- 利奈唑胺清除率从14.6 L/h降至6.2 L/h。
临床怎么用
- ICU患者使用利奈唑胺时应考虑常规TDM以指导个体化 dosing。
- 当间歇给药未达药效学目标时,可考虑连续输注,但需TDM监测避免超治疗暴露。
局限性
- 单例病例报告,结果可能不适用于所有ICU患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Linezolid is an essential antimicrobial for treating multidrug-resistant gram-positive infections in critically ill patients. However, its pharmacokinetics (PK) are highly variable, potentially leading to subtherapeutic exposure or toxicity. Therapeutic drug monitoring (TDM) plays a critical role in guiding individualized dosing. SUMMARY: We describe a 66-year-old intensive care unit (ICU) patient treated with linezolid for vancomycin-resistant Enterococcus faecium (VRE) peritonitis and empyema. Despite standard dosing (600 mg IV every 12 hours), linezolid concentrations remained below the limit of quantification for 6 days, coinciding with persistent VRE isolation. A switch to continuous infusion (CI) at 2,400 mg/day achieved therapeutic levels (mean concentration [Cmean], 6.17 mg/L), but subsequent supratherapeutic exposure (Cmean, 12.12 mg/L; 24-hour area under the curve, 290.9 mg · h/L) led to adrenergic toxicity. Linezolid clearance declined from 14.6 to 6.2 L/h, unrelated to renal function, suggesting the influence of nonlinear elimination and alternate metabolic pathways. Following empyema drainage and ketamine withdrawal, PK parameters stabilized. This case highlights the extreme intraindividual PK variability of linezolid in critical illness. Contributing mechanisms may include ROS-driven CYP2J2 upregulation in acute lung injury, autoinhibition of metabolite formation, and drug interactions. CI enabled PK and pharmacodynamic target attainment when intermittent dosing failed but required TDM to avoid overexposure. CONCLUSION: Routine TDM is essential to optimize the safely and effectively manage linezolid therapy in ICU patients. This case underscores the importance of integrating TDM with PK modeling to guide personalized dosing strategies in complex and dynamic clinical scenarios.
引用
- Muñoz-Pichuante D, Álvarez MI, Reyes Hales D, et al. Extreme variability in linezolid concentrations in the ICU: A case for routine therapeutic drug monitoring. Am J Health Syst Pharm. 2026. PMID: 40882010. doi:10.1093/ajhp/zxaf235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。